Immunodiagnostics firm strikes multi-year deal with top ten pharma group

Nottingham-headquartered immunodiagnostics company Oncimmune Holdings has signed a Master Services Agreement (MSA) to provide clinical laboratory services to a top ten pharmaceutical group.

The multi-year deal with the unnamed group will see Oncimmune support multiple autoantibody profiling projects which are currently in discussion, focusing on autoimmune, cardiovascular and prenatal diseases.

The company has also signed a new contract with a leading UK-based biotech company to collaborate on the discovery of autoantibody biomarkers for the detection of sepsis and a new commercial contract with a leading US research institution.

The value of the contracts has not been disclosed.

Based out of its research centre in Dortmund, Oncimmune’s ImmunoINSIGHTS service business leverages the company’s technology platform and methodologies across multiple diseases to offer life-science organizations actionable insights for therapies across the development and product lifecycle.

In a statement to the London Stock Exchange, the firm said the signing of the contracts had given the Board “continued confidence in the outlook for the business.”

Oncimmune began life as a spin-out from the University of Nottingham before floating on AIM in 2016.